735 results about "HeLa" patented technology

The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with cervical cancer. The biological compositions can be used to retard the growth of cervical cancer cells and/or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.

The invention provides an sgRNA combined with immunogene to inhibit high risk HPV expression, a gene knockout vector thereof, and an application of the sgRNA and the vector. The sgRNA sequences of a human papilloma virus 16 type gene suitable for CRISPR-Cas9 targeting editing and a human PD-1 gene are selected, and the plasmid vector of the sgRNA and a CRISPR-Cas9 nuclease gene expression vector are transferred to HPV16+ human cervical carcinoma cells and HPV16+ transplantation tumor-bearing mice, and can obviously inhibit HPV16 expression and inhibit tumor growth. The gene expression vector prepared in the invention has the advantages of simple method steps, good sgRNA targeting property, high CRISPR-Cas9 knockout efficiency, accurate targeting splicing of high risk HPV16 type and PD-1 genes, efficient reduction of the expression of the high risk HPV16 type gene, and obvious inhibition of the tumor growth through combined application.

The invention relates to a penicillium citrinum sourced citrinin compound (penicitrinol O) as well as a preparation method and an application thereof. The compound has an effect on inhibiting tumor cell proliferation and has anti-tumor activity, and the structural formula is shown in the specification. The preparation method comprises the steps: fermenting and culturing penicillium citrinum IBPT-5 to obtain a fermented product; and then separating and purifying the fermented product to obtain the compound. The experiment shows that the compound has high anti-tumor activity for human cervical cancer cell line hela and can be used for preparing cell proliferation inhibition medicines or anti-tumor medicines for the study on anti-tumor.

The invention discloses a targeted polypeptide capable of being specifically combined with tumors, particularly a targeted peptide capable of being specifically combined with liver cancer tissues and application thereof in diagnosis and treatment of liver cancer. The liver cancer targeted peptide is preferably HCC-47 of which the amino acid sequence is SQDIRTWNGTRS; and the liver cancer targeted peptide is specifically combined with the liver cancer tissues, and can not be specifically combined with cervical carcinoma cells Hela, mammary cancer cells MDA-MB231, kidney cancer cells CRL-1932 and lung cancer cells A549. The polypeptide is obtained by in-vitro biological elutriation by combining a bacteriophage display library and a living body cross sectioning technique. The polypeptide can be used in a molecular imaging preparation for early diagnosis of liver cancer. The polypeptide can also be used in targeted modification and preparation of drugs for treating liver cancer. The polypeptide can also be used for targeted modification on drug transport carriers, thereby providing a new way for diagnosing or treating patients with liver cancer.

The present invention relates to a pentacyclic triterpanoid derivative of multiple-oxide substitution of the A ring and the medicine salt or solvate of the derivative, and the present invention also relates to the preparation method, the drug combination, and medical use of the derivative. The compound of the present invention has the functions of inhibiting the activity of six human tumor cell strains in vitro, such as human prostate cancer cell (PC-3), nasopharyngeal carcinoma cells (CNE), oral squamous carcinoma cell(KB), human lung cancer cell (A549), human hepatoma cell (BEL-7404), and human cervix cancer cell (Hela), and the function of the invention is at the same magnitude of the positive control of cisplatin, thereby the compound can be used as expected antitumor drug. The compound of the present invention also inhibits the alpha glucosidase strongly, and the inhibiting effect is greater than the positive control of acarbose, thereby the compound can be used as expected medicine for preventing and treating diabetes and the treatment of the virus diseases.

The invention discloses a preparation method and a time-resolved biological imaging application of thermally activated delayed fluorescent (TADF) organic material-based water-soluble long-life fluorescent nanoparticles. The nanostructure of the nanoparticles is represented by figure 1, a thermally activated delayed fluorescent molecule represented by CzPy is represented by a general formula (I). The method comprises the following steps: synthesizing the pure organic TADF micro-molecular material CzPy through adopting a one-step process, and rapidly injecting a CzPy/lecithin-polyethylene glycol mixed solution to deionized water to obtain the CzPy nanoparticles with good water solubility, high luminescence intensity and long fluorescence life. HELA cell dyeing marking and zebra blood vessel imaging results show that the nanoparticles have the advantages of long fluorescence life, low cytotoxicity and biotoxicity, stable spectrum signal, realization of time-resolved fluorescence imaging in cell or in vivo imaging, and good application prospect.

An anti-cytoplasm thymidine kinase-IgY antibody prepared from the C-terminal 31 peptide of human cervical cancer cell (HeLa)TK1, the application of the reagent kit prepared from said antibody in diagnosing tumor, the process for preparing said antibody and reagent kit, and its test method are disclosed.

The invention discloses conjugates of beta-carboline-3-carboxylic acid and oligopeptides, preparation, a nano structure, and an application thereof as an antitumor agent. The invention discloses conjugates (8a-f) of beta-carboline-3-carboxylic acid and six oligopeptides, wherein the six oligopeptides are Leu-Pro-Asn-Ile-Ser-Lys-Pro (LPNISKP), Arg-Gly-Asp-Ser (RGDS), Arg-Gly-Asp-Phe (RGDF), Arg-Gly-Asp-Val (RGDV), Leu-Asp-Ser (LDV), and Lys-Glu (KE). The invention discloses a preparation method and nano structure of the conjugates, discloses an inhibition effect of the conjugates on five tumor cell strains namely HL60, HCT-8, HeLa, BEL-7402, and HepG2, and further discloses an inhibition effect on tumor growth of S180 tumor-bearing mice. The experiment results show that the provided conjugates of beta-carboline-3-carboxylic acid and six oligopeptides have an excellent antitumor effect, so that the conjugates is advantageous for being used as an antitumor drug in clinic.

The invention provides a high-specificity high-sensitivity coordinated compound anti-human-TK1 antibody prepared from an antigenic determinant composed of human cervical cancer cell TK1 monomer N-terminal 23 peptide, C-terminal 20 peptide and C-terminal 28 peptide, and application thereof in tumor diagnosis. The antigenic determinant contains the following amino acid sequences: N-terminal 23 peptide (3-25): CINLPTVLPGSPSKTRGQIQVIL, C-terminal 20 peptide (206-225) CPVPGKPGEAVAARKLFAPQ, and C-terminal 28 peptide (198-225) AGPDNKENCPVPGKPGEAVAARKLFAPQ. The invention also relates to a method for preparing the antibody prepared from the antigen. The antibody kit provided by the invention has the characteristics of high sensitivity, high specificity, low cost and the like. The treatment effect on the tumor patient is evaluated by an enhanced chemiluminescent point blotting detection method, immunohistochemical detection and the detection kit.

The invention relates to the synthesis of an emodin derivative with anticancer function, in particular to beta-hydroxy protected didecyl quaternary ammonium salt with anticancer activity and a preparation method thereof. The didecyl quaternary ammonium salt is methyl didecyl-[2-(4,5-dihydroxy-7-methoxy-9,10-anthraquinonyl)methyl] ammonium salt and is prepared from emodin serving as a raw materialthrough a series of synthetic reactions. In the invention, the emodin derivative has proliferation inhibiting functions with different degrees for five cancer cells such as liver cancer HepG2, gastric cancer BGC, neuroma SH-SY5Y, gastric cancer AGS and cervical cancer Hela and the normal human embryonic lung fibroblast HELF, and can be used for preparing medicaments for treating cancers.

The invention discloses water-soluble perylene imide compounds, a usage as a DNA intercalator, and applications thereof in the growth inhibition of cancer cells, and belongs to the technical field of chemical synthesis of biological drugs. Through inducing cation amino functional groups into perylene anhydride derivatives and a perylene mono-anhydride system, the water solubility of the perylene anhydride derivatives and the perylene mono-anhydride system is greatly improved; furthermore, the cation amino functional groups are in a photo-stability combination with perylene derivatives, and thus a series of novel water-soluble perylene imide compounds are obtained. The synthesized water-soluble perylene imide compounds can effectively be embedded between the base pairs of DNA double helix of nucleus and be used as a DNA intercalator. The synthesized water-soluble perylene imide compounds have a planar rigid structure, so that the compounds can be specifically enriched around fixed tissue cell nucleus, the compounds have the advantages of strong fluorescence and easiness in fluorescent imaging, and have a similar effect as the DAPI effect of commercial cell nucleus dye. The synthesized water-soluble perylene imide compounds can effectively inhibit the growth of cancer cells such as U2OS, HTC116, Hela, AGS, etc., and have a very prominent anti-tumor effect.

The invention provides a high-specificity and high-sensitivity coordination combination anti-human TK1 antibody prepared from an antigenic determinant consisting of 23 peptide at an N end, 20 peptide at a C end and 28 peptide at the C end of human cervical cancer cells, and application thereof to tumor diagnosis. The antigenic determinant comprises the following amino acid sequences: 1) the 23 peptide (3-25) at the N end: CINLPTVLPGSPSKTRGQIQVIL: 2) the 20 peptide (206-225) at the C end: CPVPGKPGEAVAARKLFAPQ; and 3) the 28 peptide at the C end: AGPDNKENCPVPGKPGEAVAARKLFAPQ. The invention simultaneously provides a method applying the antigen for preparing the antibody. An antibody kit provided by the invention has the characteristics of high sensitivity, high specificity, low cost and the like, tumor rehabilitation populations are periodically monitored by an enhanced chemiluminescence dot blot detection method, immunohistochemistry detection and the detection kit, and the recurrence and transfer risk and the prognosis of the tumor rehabilitation people are evaluated.

Described herein are devices and methods for extracting cellular material from living cells and then depositing them into to a receptacle in a nanoliter scale. Using a nanopipette integrated into a scanning ion conductance microscope (SICM), extraction of mitochondrial DNA from human BJ fibroblasts and Green Fluorescent Protein (GFP) transcripts from HeLa/GFP cells was achieved with minimal disruption to the cellular milieu and without chemical treatment prior to obtaining the isolated sample. Success of the extraction was confirmed by fluorescence microscopy and PCR analysis of the extracted material. The method and apparatus may be applied to many different cell types and intracellular targets, allowing not only single cell analysis, but single subcellular compartment analysis of materials extracted in their native state.

Cervical cancer cells and HPV⁺ head and neck cancer cells express three testis-specific genes not normally expressed in somatic cells: testicular cell adhesion molecule 1 (TCAM1), synaptonemal complex protein 2 (SYCP2) and stromal antigen 3 (STAG3). Among the three markers, TCAM1 and SYCP2 are early detection markers. Various methods for identifying a human or non-human animal as a candidate for further examination for cervical cancer, preneoplastic lesion for cervical cancer, head and neck cancer, or preneoplastic lesion for head and neck cancer are disclosed. Methods of detecting said cancers and preneoplastic lesions, methods of screening for drugs for treating said cancers and preneoplastic lesions, methods for monitoring the effectiveness of a treatment for said cancers, and methods of treating said cancers are also disclosed. Further disclosed are kits that can be used to practice the above methods.

In this patent, we isolated a novel compound from fruiting body of Antrodia cinnamomea, namely, (22R)-5α-lanosta-8,24-dien-3β,15α,21-triol. This compound possesses preferential cytotoxicity against human leukemia, pancreatic cancer, esophageal cancer, hepatoma, and cervical cancer cells.

The invention provides a chestnut seed alpha-1,6-glucan, a preparation method for the chestnut seed alpha-1,6-glucan, and application of the chestnut seed alpha-1,6-glucan to anticancer drugs. The structural formula of the chestnut seed alpha-1,6-glucan is [arrow 6)-alpha-Glcp(1 arrow]n, the weight average molecular weight is in the range of 1600-2400 kDa, and the average molecular weight is 2000 kDa; the chestnut seed alpha-1,6-glucan belongs to homopolysaccharides, and has obvious inhibited activity on proliferation of cervical cancer cells HeLa, breast cancer cells MCF-7 and adriamycin-resistant human breast cancer cell MCF-7 in vitro; chestnut is a rare fruit with the edible Chinese herbal function, and has no serious toxic and side effect; the chestnut seed alpha-1,6-glucan obtained according to the preparation method provided by the invention is high in sugar chain structural integrity, and is expected to be developed into anticancer drugs or assisted anticancer drugs.

The invention discloses target specific double mutant fusion protein, which is established by human gonadotropin releasing hormone mutant (mGnRH) and recombinant pseudomonas aeruginosa exotoxin A mutant (PE38m4a) fusion protein. The mGnRH-PE38m4a protein provided by the invention has obvious specific binding activity and cytotoxicity to the tumor cell lines which comprise colon cancer HT-29 cells, oophoroma OVCAR3 cells, cervical adenocarcinoma HeLa cells or liver cancer HepG-2 cells, and the like; the normal cells basically have no lethal function; the activity of the fusion protein is enhanced by approximate nine to ten times compared with the activity of natural PEA; the cost is low, the method is simple, therefore the target specific double mutant fusion protein is more suitable for industrialized production.

The invention discloses a mercaptyl-terminated (2-dimethylamino ethyl) polymethacrylic ester polymer, a self-assembled and modified nano-gold compound (PDMAEMAGNPs) of the polymer as well as a compound of the polymer and plasmid DNA; and the invention also discloses preparation methods of the polymer and the compounds as well as the application of all in carrier as genes. When the concentration ofthe compounds of PDMAEMAGNPs and GFP DNA (green fluorescent protein expression DNA) is 30Mug/mL, the transfection efficiency to HEK 293T cell is 30 percent, and the survival rate to HEK 293T cell, HeLa cell and 293 cell is more than 80 percent. The PDMAEMAGNPs/CpG ODN (human CpG oligodeoxynucleotide) compound has remarkable effects in gene therapy in vitro and in vivo. The suppression ratio to tumor growth of the PDMAEMAGNPs/p53 DNA (tumor suppressor gene) is 30-37 percent.